1. Scrip
  2. >>Business
  3. >>Earnings

Merck KGaA Sticks With Structure, Eyes Smaller Healthcare Deals

 
• By Kevin Grogan

There may be a trend towards spinning off business units but Merck continues to sees its three-pillar structure as providing the best protection from downturns in any individual segment.

Helene von Roeder
Helene von Roeder • Source: Merck KGaA

While a number of industry heavyweights such as Bayer AG and Sanofi are weighing up options to split up their key business units, Merck KGaA will be sticking to its diversified business model.

There are changes afoot at fellow German multi-pillar group Bayer and earlier this week, new CEO Bill Anderson outlined plans...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.